X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
According to the agreement, Porton Advanced will provide services of development, and production in China with Ascle Therapeutics' NK cell project, supporting the application of NK cells in cancer prevention, anti-aging.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Ascle Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 20, 2023
Details:
The partnership will enhance the cell and gene therapy pipelines, including BRL-101, which was developed using the in-house ModiHSC® hematopoietic stem cell platform, from BRL Medicine from clinical trials to further expedite the commercialization of innovative therapies.
Lead Product(s): BRL-101
Therapeutic Area: Genetic Disease Product Name: BRL-101
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BRL Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership September 14, 2023
Details:
The partnership aims to accelerate the development of T-cell therapies for tumors and autoimmune diseases. Porton Advanced will provide CDMO services for multiple pipelines for gene and cell therapy, including plasmids, virus, TIL, TCR-T, and Treg, to Bennu Biotherapeutics.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bennu Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 13, 2023
Details:
Through the partnership, Porton will assist Bennu in accelerating and focusing on the development of T-cell therapies for the treatment of solid tumors.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Bennu Biotherapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 13, 2023
Details:
Through the partnership, Porton will assist BRL Medicine's lead candidate BRL-101, which is a BCL11A gene inhibitor. It is being evaluated in the clinical trial studies for the treatment of Beta-Thalassemia and Sickle Cell Disease.
Lead Product(s): BRL-101
Therapeutic Area: Genetic Disease Product Name: BRL-101
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: BRL Medicine Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 03, 2023
Details:
Under the terms of the collaboration, Porton Advanced Solutions and DanausGT Biotechnology will expedite the development of innovative therapeutics in gene and cell therapy pipelines.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: DanausGT Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 02, 2023
Details:
This collaboration will accelerate the development of innovative therapeutics for the treatment of some diseases such as blood, skin, and liver-related diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Hematology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: DanausGT Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 02, 2023
Details:
The strategic collaboration will further integrate the resources and capabilities of both parties, jointly promote the establishment of microbial vectors used for gene therapy and mRNA drug platform technology, and accelerate the R&D process of bioinnovative drugs.
Lead Product(s): MV-based mRNA Therapeutic
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Suzhou Royaltech Med Co., Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 29, 2022
Details:
According to the agreement, Proton Bio will provide Shengnuo Pharmaceutical with research and development services for the development, production and registration and approval of cell therapy drugs, including SND002.
Lead Product(s): SND002
Therapeutic Area: Oncology Product Name: SND002
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Guizhou Sinorda Biomedicine Co. Ltd
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership April 22, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
